Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05349669
Other study ID # ANTHEAHOSPITAL12022022
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 30, 2022
Est. completion date September 15, 2022

Study information

Verified date February 2023
Source Anthea Hospital Bari
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ dysfunction. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. Jafron is a device designed to remove cytokine from the blood using haemoadsorption (HA). This preliminary report aims to evaluate the potential of Jafron to decrease peri-operative cytokine levels in cardiac surgery.


Description:

In this context the investigators introduce the study design for multi-centre pilot randomized report in 40 patients undergoing elective CPB procedures with an expected time >120 minutes for each extracorporeal procedure. Patients will be randomly allocated to either standard of care (n = 20) or Jafron HA(n = 20) during cardiopulmonary bypass (CPB). The primary outcome will be the difference between the two groups in cytokines levels (IL-2, IL-6,TNF-α, IFN gamma) and secondary parameters (Fibrinogen, Albumin, Platelets, Hemoglobin, Hematocrit, White Blood Cells, Neutrophils,Lymphocytes, Monocytes, Eosinophils, Basophils) will measured at anaesthesia induction, at the endof CPB , Primary outcomes: hemodynamics with or without vasoconstrictors use, the mechanical ventilation (MV) (hours) time and length of stay in intensive care unit (ICU) (hours). This prospectivemulti-centre randomized controlled report will take place in two Centres: Anthea Hospital, GVMCare & Research, Bari, Italy; Virgen de la Arrixaca University Hospital, Murcia, Spain; between May 2022 and September 2022. The target population per centre will include (n=20) patients; will beallocate for each center to either standard of care (n = 10) or Jafron HA (n = 10) planned for elective cardiac surgery with increased risk of cytokine release.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 15, 2022
Est. primary completion date September 15, 2022
Accepts healthy volunteers No
Gender All
Age group 10 Years to 100 Years
Eligibility Inclusion Criteria : - elective cardiac surgery under CPB - double valve replacement or a complex surgery with an expected CPB duration > 120 min - redo cardiac surgery Exclusion criteria: - end-stage renal disease (dialysis dependence) - active infectious endocarditis - emergency or off-pump procedure - prescription of non-steroidal antiinflammatory medication (except for low-dose aspirin) or corticosteroids within 7 days - enrolment in another conflicting study - administration of human albumin during CPB

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Jafron use during CPB
Use of filter Jafron during CPB

Locations

Country Name City State
Italy Anthea Hospital Bari Apulian

Sponsors (1)

Lead Sponsor Collaborator
Anthea Hospital Bari

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary cytokines levels IL-2, IL-6,TNF-a, IFN gamma 1 hour before start of the cardiopulmonary bypass
Primary cytokines levels IL-2, IL-6,TNF-a, IFN gamma, 10 minutes after stop the cardiopulmonary bypass
Primary Hemodynamics supports vasoconstrictors use or not use 10 minutes after stop of the cardiopulmonary bypass
Primary Post-operative ITEMS in intensive care unit mechanical ventilation (MV) (hours) time and length of stay in intensive care unit (ICU) (hours) 3 days after surgery
Secondary Markers levels Concentration of Fibrinogen, Albumin, Platelets, Hemoglobin, Hematocrit, White Blood Cells, Neutrophils,Aptoglobin, Cell free Hemoglobin Lymphocytes, Monocytes, Eosinophils, Basophils 1 day before start of the cardiopulmonary bypass
Secondary Markers Concentration of Fibrinogen, Albumin, Platelets, Hemoglobin, Hematocrit, White Blood Cells, Neutrophils,Aptoglobin, Cell free Hemoglobin Lymphocytes, Monocytes, Eosinophils, Basophils 1 day after stop the cardiopulmonary bypass
Secondary Hemodynamics supports Need of vasoconstrictors 1 hour after stop the cardiopulmonary bypass
See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Terminated NCT04540120 - Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome Phase 2
Terminated NCT03557749 - Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04975555 - Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Phase 2
Terminated NCT04403685 - Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Phase 3
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT04720378 - Safety and Tolerability Study of IV ST266 in COVID-19 Subjects Phase 1
Terminated NCT04415073 - A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 Phase 2
Completed NCT03533101 - Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Phase 1/Phase 2
Completed NCT04403061 - Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Terminated NCT04377503 - Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Phase 2
Completed NCT04475588 - Efficacy and Safety of Itolizumab in COVID-19 Complications Phase 2
Recruiting NCT04781803 - Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome Phase 2
Completed NCT01353157 - Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Recruiting NCT04048434 - Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) N/A
Recruiting NCT04486521 - Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19